Evidence map›Paper›PMID 40251524›Full record

ArticleCellular & molecular biology letters2025

Exploring the role of gut microbiota modulation in the long-term therapeutic benefits of early MSC transplantation in MRL/lpr mice.

Quanren Pan, Fengbiao Guo, Jiaxuan Chen, Haimin Huang, Yanyan Huang, Shuzhen Liao, Zengzhi Xiao, Xi Wang, Liuyong You, Lawei Yang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Quanren Pan *Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Fengbiao Guo *Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Jiaxuan Chen *Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Haimin HuangGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yanyan HuangGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Shuzhen LiaoGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Zengzhi XiaoGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Xi WangGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Liuyong YouDepartment of Clinical Laboratory, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lawei YangGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Xuemei HuangDepartment of Anesthesiology, First People's Hospital of Foshan, Foshan, Guangdong, China.
Haiyan XiaoDepartment of Cellular Biology and Anatomy, James and Jean Culver Vision Discovery Institute, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Hua-Feng LiuGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. liuhf@gdmu.edu.cn.
Qingjun PanGuangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. stilwapan@gmail.com.ORCID http://orcid.org/0000-0002-8060-9099

Funding

Guangdong Basic and Applied Basic Research Foundation Enterprise Joint Fund 2022A1515220028Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases 2022B1212030003National Natural Science Foundation of China 82070757National Natural Science Foundation of China 82270770National Natural Science Foundation of China 82400841Zhanjiang Science and Technology Project (Competitive) 2021A05060
6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE), influenced by gut microbiota dysbiosis, is characterized by autoimmune and inflammatory responses. Human umbilical cord-derived mesenchymal stem cell (hUC-MSC) transplantation is an effective and safe treatment for refractory or severe SLE; however, the long-term efficacy and mechanisms of early hUC-MSC therapeutic benefits in SLE need further investigation.

methodsHere, lupus-prone MRL/MpJ-Fas

resultsOur results showed that early MSC treatment extended therapeutic effects up to 12 weeks, reducing autoantibodies, proinflammatory cytokines, B cells, and improving lupus nephritis. It also modulated the gut microbiota, increasing the abundance of beneficial bacteria, such as Lactobacillus johnsonii and Romboutsia ilealis, which led to higher levels of plasma tryptophan and butyrate metabolites. These metabolites activate the aryl hydrocarbon receptor (AHR), upregulate the Cyp1a1 and Cyp1b1 gene, enhance the zonula occludens 1 (ZO-1) protein, promote intestinal repair, and mitigate SLE progression. Notably, FMT from lupus mice significantly reversed hUC-MSC benefits, suggesting that the modulation of the gut microbiota plays a crucial role in the therapeutic response observed in MRL/lpr mice.

conclusionsThis research innovatively explores the early therapeutic window for MSCs in SLE, highlighting the partial mechanisms through which hUC-MSCs modulate the gut microbiota-tryptophan-AHR axis, thereby ameliorating SLE symptoms.

Indexed as

Gastrointestinal MicrobiomeLupus Erythematosus, SystemicMesenchymal Stem Cell TransplantationAnimalsCytokinesDisease Models, AnimalFecal Microbiota TransplantationFemaleHumansMesenchymal Stem CellsMiceMice, Inbred MRL lprReceptors, Aryl HydrocarbonCytokinesReceptors, Aryl HydrocarbonAryl hydrocarbon receptorButanoate metabolismGut microbiotaMesenchymal stem cellsSystemic lupus erythematosusTryptophan metabolism

Identifiers

PMID40251524
PMCPMC12007202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.